Novo Nordisk Plans $2.6-Bn Mfg Expansion
Novo Nordisk plans to invest more than DKK 17 billion ($2.6 billion) to construct three new manufacturing facilities and to expand one existing facility at its production site in Kalundborg, Denmark.
The investment will establish additional capacity across the company’s entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity. These expansions will provide capacity for the production of Novo Nordisk’s current and future oral and injectable products.
The investment projects are expected to be finalized in 2027 and will create around 400 new jobs. More than 2,500 external staff will be engaged in the building phase.
Novo Nordisk’s production facilities in Kalundborg cover an area of 1,200,000 m2 and employ about 3,200 people. In Kalundborg, Novo Nordisk manufactures products for the treatment of obesity and diabetes as well as several biopharmaceutical products.
Source: Novo Nordisk
